- Home
- VYGR vs DENN Comparison
VYGR vs DENN Comparison
Compare VYGR & DENN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- DENN
- Stock Information
- Founded
- VYGR 2013
- DENN 1953
- Country
- VYGR United States
- DENN United States
- Employees
- VYGR N/A
- DENN N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- DENN Restaurants
- Sector
- VYGR Health Care
- DENN Consumer Discretionary
- Exchange
- VYGR Nasdaq
- DENN Nasdaq
- Market Cap
- VYGR 206.9M
- DENN 211.7M
- IPO Year
- VYGR 2015
- DENN 1989
- Fundamental
- Price
- VYGR $4.24
- DENN $4.61
- Analyst Decision
- VYGR Strong Buy
- DENN Strong Buy
- Analyst Count
- VYGR 7
- DENN 7
- Target Price
- VYGR $14.50
- DENN $6.96
- AVG Volume (30 Days)
- VYGR 678.8K
- DENN 661.8K
- Earning Date
- VYGR 08-06-2025
- DENN 10-21-2025
- Dividend Yield
- VYGR N/A
- DENN N/A
- EPS Growth
- VYGR N/A
- DENN N/A
- EPS
- VYGR N/A
- DENN 0.30
- Revenue
- VYGR $42,580,000.00
- DENN $455,727,000.00
- Revenue This Year
- VYGR N/A
- DENN $7.57
- Revenue Next Year
- VYGR $107.07
- DENN $1.89
- P/E Ratio
- VYGR N/A
- DENN $15.34
- Revenue Growth
- VYGR N/A
- DENN 0.06
- 52 Week Low
- VYGR $2.65
- DENN $2.85
- 52 Week High
- VYGR $8.28
- DENN $7.73
- Technical
- Relative Strength Index (RSI)
- VYGR 70.98
- DENN 59.75
- Support Level
- VYGR $3.32
- DENN $4.31
- Resistance Level
- VYGR $3.49
- DENN $4.61
- Average True Range (ATR)
- VYGR 0.23
- DENN 0.23
- MACD
- VYGR 0.06
- DENN 0.04
- Stochastic Oscillator
- VYGR 94.03
- DENN 63.49
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About DENN Denny's Corporation
Denny's Corp is America's franchised full-service restaurant chains based on the number of restaurants. The company owns and operates the Denny's brand and the Keke's Breakfast Cafe brand. It provides Pancakes, Appetizers & Soups, Sandwiches & Salads, Breakfast Melts, Omelets, and others. The company generates its revenue from two sources: the sale of food and beverages and the collection of royalties, advertising revenue, initial and other fees, including occupancy revenue, from restaurants operated by their franchisees. Geographically operates in USA states as well as globally like Canada, Mexico, Guatemala, Indonesia, United Kingdom, New Zealand and others. Maximum revenue is from USA and Canada.